Supernus Pharmaceuticals (SUPN) Tax Provisions (2011 - 2025)

Supernus Pharmaceuticals (SUPN) has 12 years of Tax Provisions data on file, last reported at $2.2 million in Q4 2025.

• Tax Provisions for Q4 2025 came in at $2.2 million, down 79.92% year-over-year; the trailing twelve-month figure through Dec 2025 was -$10.5 million (down 143.59% YoY), and the FY2025 annual result was -$10.5 million, down 143.66% from the prior year.
• Tax Provisions grew to $2.2 million in Q4 2025 per SUPN's latest filing, from -$12.8 million in the prior quarter.
• Over five years, Tax Provisions peaked at $25.9 million in Q3 2023 and troughed at -$16.3 million in Q2 2023.
• A 5-year average of $1.7 million and a median of $2.9 million in 2022 frame the typical range for Tax Provisions.
• The sharpest annual moves came in 2023 and 2024: Tax Provisions tumbled 565.6% in 2023, then surged 7619.73% in 2024.
• A 5-year view of Tax Provisions shows it stood at -$391000.0 in 2021, then surged by 2563.43% to $9.6 million in 2022, then sank by 101.53% to -$147000.0 in 2023, then surged by 7619.73% to $11.1 million in 2024, then sank by 79.92% to $2.2 million in 2025.
• Business Quant data shows SUPN's Tax Provisions at $2.2 million in Q4 2025, -$12.8 million in Q3 2025, and -$5.8 million in Q2 2025.